Seattle, WA -- (SBWIRE) -- 12/10/2019 -- Sjogren's Syndrome is an autoimmune disease. This means that your immune system attacks parts of your own body by mistake. In Sjogren's Syndrome, it attacks the glands that make tears and saliva. This causes a dry mouth and dry eyes. You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves.

For Free PDF Brochure and More Detailes of Key Players: https://www.worldwidemarketreports.com/sample/245089

Sjogren's Syndrome is a multisystem disorder that is heterogeneous in its presentation, course, and outcome. There is still no single clinical, laboratory, pathological, or radiological feature that could serve as a 'gold standard' for the diagnosis and/or classification of this syndrome. Labial salivary gland biopsy with a subsequent histopathological evaluation is currently in use. Consequently, the development of criteria for use in both clinical care, as well as research studies, has been an important challenge in Sjogren's Syndrome.

Hitherto, the therapeutic market size of Sjogren's Syndrome is mainly accounted by symptomatic treatment including local therapies (pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others), systemic therapies (corticosteroids, hydroxychloroquine) and immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid) which are commonly used interventions.

Moreover, biological therapy with Rituximab is in extensive use for the US market.

The report offers a complete analysis of various companies including: Allergan, Biogen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Novartis

'Sjogren's Syndrome' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Sjogren's Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Asia Pacific.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Sjogren's Syndrome from 2017 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Key highlights of the global Sjogren's Syndrome market for the forecast years 2018-2027:
- CAGR of the market during the forecast period 2018-2027
- Detailed information on factors that will accelerate the growth of the Sjogren's Syndrome market during the next five years
- Precise estimation of the global Sjogren's Syndrome market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- Growth of the Sjogren's Syndrome industry across the Americas, APAC, and EMEA
- A thorough analysis of the market's competitive landscape and detailed information on several vendors
- Comprehensive details on the factors that will challenge the growth of Sjogren's Syndrome companies

Place an Inquire for Full ToC: https://www.worldwidemarketreports.com/quiry/245089

Customisation of the Report
In case of any queries or customisation requirements please connect with our sales team, who will ensure that your requirements are met.